Biosimilars
•11 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (11)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
|
$218.36B |
$128.44
+2.38%
|
|
AMGN
Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
|
$171.06B |
$319.44
+0.54%
|
|
VTRS
Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
|
$13.58B |
$11.69
+0.34%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.69B |
$14.04
+0.18%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
|
$3.83B |
$12.36
+1.23%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$1.86B |
$7.21
+0.63%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.74B |
$46.25
-1.72%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.17B |
$26.09
+3.26%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$403.51M |
$7.17
+2.21%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$96.30M |
$1.43
+6.72%
|
|
SCNX
Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
|
$9.77M |
$0.56
-8.33%
|
Loading company comparison...
Loading industry trends...
Loading research report...
